Self-monitoring and treatment of chronic non-communicable diseases in the context of the COVID-19 pandemic. Consensus of experts of the National society of evidence-based pharmacotherapy and the Russian society of the prevention of non-communicable diseases

In the current epidemic of a new coronavirus infection, COVID-19 treatment of patients with chronic non-communicable diseases (NCDS) and cardiovascular diseases (CVD), in particular, requires close attention of doctors. The main objectives of such patients’ management tactics are to ensure that patients comply with self-isolation measures that prevent infection, motivate patients to follow all medical recommendations. Special attention should be paid to comply with recommended treatment of CVD. In the case of an infectious disease, it is necessary to assess the prescribed therapy for interaction with medications already taken by the patient. However, the tactics for COVID-19 therapy, including in patients with NCDS, may change over time, since there are currently no drugs with proven effectiveness for the treatment of a new coronavirus infection.

Download Full-text

Health promotion and prevention of chronic non-communicable diseases in the context of the COVID-19 pandemic. Consensus of experts of the National society of evidence-based pharmacotherapy and the Russian society of the prevention of non-communicable diseases

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2020-2605 ◽

2020 ◽

Vol 19 (3) ◽

pp. 2605

Author(s):

O. M. Drapkina ◽

M. G. Gambaryan ◽

B. E. Gorny ◽

N. S. Karamnova ◽

A. V. Kontsevaya ◽

...

Keyword(s):

Health Promotion ◽

Communicable Diseases ◽

Evidence Based ◽

Russian Society ◽

National Society ◽

Non Communicable Diseases

Download Full-text

PT332 An Integrated Potential Monitoring System for the Pan-India Capacity Building Initiative for Primary Care Physicians in Non-Communicable Diseases- Evidence Based Diabetes Management

Global Heart ◽

10.1016/j.gheart.2014.03.2062 ◽

2014 ◽

Vol 9 (1) ◽

pp. e231

Author(s):

Rakesh Mehra ◽

Shivangi Vats ◽

Shreyas Sharma

Keyword(s):

Primary Care ◽

Capacity Building ◽

Monitoring System ◽

Primary Care Physicians ◽

Diabetes Management ◽

Communicable Diseases ◽

Evidence Based ◽

Non Communicable Diseases ◽

Potential Monitoring

Download Full-text

Towards evidence‐based integration of services for HIV, non‐communicable diseases and substance use: insights from modelling

Journal of the International AIDS Society ◽

10.1002/jia2.25525 ◽

2020 ◽

Vol 23 (S1) ◽

Author(s):

David W Dowdy ◽

Kimberly A Powers ◽

Timothy B Hallett

Keyword(s):

Substance Use ◽

Communicable Diseases ◽

Evidence Based ◽

Non Communicable Diseases ◽

Integration Of Services

Download Full-text

Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts’ Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association

Kardiologiia ◽

10.18087/cardio.2020.6.n1180 ◽

2020 ◽

Vol 60 (6) ◽

pp. 4-14 ◽

Cited By ~ 3

Author(s):

Ye. V. Shlyakhto ◽

G. P. Arutyunov ◽

Yu. N. Belenkov ◽

E. I. Tarlovskaya ◽

A. O. Konradi ◽

...

Keyword(s):

Drug Interaction ◽

Antithrombotic Therapy ◽

Antiarrhythmic Drugs ◽

Antiviral Drug ◽

Heart Rhythm ◽

Antiviral Drugs ◽

Russian Society ◽

National Society ◽

Heart Rhythm Disorders ◽

Coronavirus Infection

This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.

Download Full-text

The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2021-3172 ◽

2022 ◽

Vol 20 (8) ◽

pp. 3172

Author(s):

O. M. Drapkina ◽

L. Y. Drozdova ◽

S. N. Avdeev ◽

S. A. Boytsov ◽

E. S. Ivanova ◽

...

Keyword(s):

General Practitioners ◽

Primary Care Physicians ◽

Communicable Diseases ◽

Clinical Aspects ◽

Non Communicable Diseases ◽

Family Doctors ◽

National Medical ◽

Coronavirus Infection ◽

Overall Mortality

Guidelines were approved at the meeting of the academic council of the National Medical Research Center for Therapy and Preventive Medicine, Moscow (Protocol No. 10 of 19.10.2021).The aim of these guidelines is to provide primary care physicians with scientifically based algorithms for the implementation of dispensary monitoring in patients with chronic non-communicable diseases in the conditions of the new coronavirus infection (COVID-19) pandemic, including the use of telemedicine technologies.The organization and conduct of high-quality medical follow-up are the most important tasks aimed at both reducing the risks of developing complications of chronic non-communicable diseases and reducing overall mortality, especially in the current conditions of the COVID-19 pandemic. The guidelines contain clinical aspects of dispensary follow-up, general principles of tactics for managing patients with various chronic non-communicable diseases in COVID-19 conditions, in addition, brief checklists with options for interviewing patients with various chronic non-communicable diseases are presented, topical aspects of the interaction of drugs used in the treatment of chronic non-communicable diseases with antiviral drugs are considered.The guidelines are intended for general practitioners, district therapists, general practitioners (family doctors), as well as doctors of other specialties providing primary health care.

Download Full-text

Evidence-based public policy making for medicines across countries: findings and implications for the future

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2020-0273 ◽

2021 ◽

Author(s):

Brian Godman ◽

Joseph Fadare ◽

Hye-Young Kwon ◽

Carolina Zampirolli Dias ◽

Amanj Kurdi ◽

...

Keyword(s):

Public Policy ◽

Policy Making ◽

Communicable Diseases ◽

Evidence Based ◽

Orphan Diseases ◽

Non Communicable Diseases ◽

Multiple Measures ◽

Universal Healthcare ◽

New Models ◽

Managed Entry Agreements

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

Download Full-text